Scarica l'app Stockscreener
273.00
1.92%
-5.35
Dopo l'orario di chiusura:
273.00
Precedente Chiudi:
$278.35
Aprire:
$275.38
Volume 24 ore:
751.27K
Relative Volume:
0.85
Capitalizzazione di mercato:
$13.03B
Reddito:
$4.03B
Utile/perdita netta:
$-182.84M
Rapporto P/E:
-72.60
EPS:
-3.7603
Flusso di cassa netto:
$391.29M
1 W Prestazione:
-6.94%
1M Prestazione:
-1.44%
6M Prestazione:
+63.11%
1 anno Prestazione:
+78.12%
Intervallo 1D:
$272.06
$275.88
Intervallo di 1 settimana:
$272.06
$291.69
Portata 52W:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
273.00 | 13.29B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
603.18 | 223.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.53 | 144.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
326.14 | 47.61B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
257.30 | 42.30B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
143.12 | 40.81B | 7.23B | 1.41B | 1.09B | 4.979 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Aggiornamento | CLSA | Hold → Outperform |
| 2026-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-17 | Aggiornamento | Argus | Hold → Buy |
| 2025-11-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Labs stock trades near TD Cowen target as Amundi trims position - ad-hoc-news.de
Charles River Labs stock heads into the open after a 0.3 percent dip - ad-hoc-news.de
Charles River Labs stock trades near TD Cowen target after recent gains - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Laboratories International (CRL) Could Be 8% Undervalued After Endosafe Automation Ramp - simplywall.st
One investor controls millions of Charles River (NYSE: CRL) shares - Stock Titan
Charles River Launches Automated Endosafe Manufacturing Suite - Contract Pharma
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite - Investing News Network
Charles River Laboratories Inte (CRL): Analyst Consensus and Growth Potential Amidst Market Volatility - DirectorsTalk Interviews
Charles River Labs stock holds steady as investors look to recent earnings - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Charles River Labs stock trades near yearly high as analysts flag valuation risks - ad-hoc-news.de
Charles River Laboratories stock gains as valuation stretches above fair value estimates - ad-hoc-news.de
How Investors Are Reacting To Charles River (CRL) Deepening Its Role In Complex Vaccine Development - simplywall.st
Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
LRT Capital Management, LLC's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Is This the Right Time to Add CRL Stock to Your Portfolio? - TradingView
Charles River Labs stock holds near recent highs as earnings beat and analyst optimism support the r - ad-hoc-news.de
Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories (CRL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations - DirectorsTalk Interviews
Charles River Laboratories (CRL) Earnings History & Trends - 24/7 Wall St.
Resilient Charles River Labs stock trades close to its 52-week high as analysts see limited upside - AD HOC NEWS
Charles River (NYSE: CRL) director exercises options, sells stock at $300 - Stock Titan
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock? - Barchart.com
Charles River (NYSE: CRL) director plans new sale after $24.8M stock sales - Stock Titan
Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Charles River and Medigen partner to speed up next-generation Enterovirus vaccine - Indian Pharma Post
Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing? - simplywall.st
Charles River Labs stock holds close to new 52-week high as Q2 2026 beat and guidance hike support r - ad-hoc-news.de
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge? - Yahoo Finance
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - ad-hoc-news.de
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Labs CEVP Parisotto sells $599,710 in shares - Investing.com
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing - marketscreener.com
Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan - Stock Titan
Charles River (NYSE: CRL) director exercises options, sells 573 shares - Stock Titan
Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment - Ad-hoc-news.de
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):